Recent Finacing
Recent Raise
BeiGene is a clinical-stage oncology R&D company developing oral small-molecule inhibitors (BTK, BRAF, PARP) and monoclonal antibodies (including PD‑1), supporting programs with global clinical development and CMC capabilities.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
